Health Care & Life Sciences » Pharmaceuticals » Pfizer | Top pharma deals yet to close worldwide by value Q1 2017

Value of top 10 yet to close pharmaceutical deals Q1 2017

Top 10 yet-to-close pharmaceutical deals worldwide based on value announced in the first quarter of 2017 (Figures expressed in billions of U.S. dollars, unless otherwise specified)

The data shows the top 10 yet to close pharmaceutical deals worldwide based on value announced in the first quarter of 2017. Johnson & Johnson has bid a deal for Actelion valued at 30 billion USD.

Johnson & Johnson (Actelion) 30
Cinven Partners LLP and Bain Capital Lp (STADA Arzneimittel AG) 5.6
Ipsen S.A. (Merrimack Pharmaceuticals Inc.- oncology assets) 1
Creat Group Corp. (Biotest AG) 1
Sanpower Group Co. Ltd (Valeant Pharmaceuticals International Inc.-oncology assets) 0.8
Celgene Corp. (Delinia Inc.) 0.8
Investor group including Giant Star Global Ltd. and Lucky Ltd. (Shandong Luoxin Pharmaceutical Group Co., Ltd) 0.3
Liu Xicheng (Hainan Haiyao Co. Ltd 10%) 0.3
Otsuka (Neurovance) 0.3
Generex Biotechnology Corp. (Emmaus Medical Inc. 51%) 0.2

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.